(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
0.75% HKD 6.76
Live Chart Being Loaded With Signals
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 39.72M |
Średni wolumen | 39.90M |
Kapitalizacja rynkowa | 80.28B |
EPS | HKD0 ( 2024-03-19 ) |
Następna data zysków | ( HKD0.150 ) 2024-05-22 |
Last Dividend | HKD0.140 ( 2023-09-07 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 12.75 |
ATR14 | HKD0.00900 (0.13%) |
Wolumen Korelacja
CSPC Pharmaceutical Group Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CSPC Pharmaceutical Group Korelacja - Waluta/Towar
CSPC Pharmaceutical Group Finanse
Annual | 2023 |
Przychody: | HKD34.75B |
Zysk brutto: | HKD24.51B (70.51 %) |
EPS: | HKD0.550 |
FY | 2023 |
Przychody: | HKD34.75B |
Zysk brutto: | HKD24.51B (70.51 %) |
EPS: | HKD0.550 |
FY | 2022 |
Przychody: | HKD35.98B |
Zysk brutto: | HKD25.88B (71.94 %) |
EPS: | HKD0.590 |
FY | 2021 |
Przychody: | HKD27.87B |
Zysk brutto: | HKD21.14B (75.84 %) |
EPS: | HKD0.470 |
Financial Reports:
No articles found.
CSPC Pharmaceutical Group Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.100 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.110 (N/A) |
HKD0.140 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0365 | 2003-08-28 |
Last Dividend | HKD0.140 | 2023-09-07 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 21 | -- |
Total Paid Out | HKD1.673 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.25 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.59 | |
Div. Directional Score | 8.48 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6821.HK | Ex Dividend Knight | 2023-06-15 | Annually | 0 | 0.00% | |
1929.HK | Ex Dividend Knight | 2023-07-12 | Semi-Annually | 0 | 0.00% | |
0954.HK | No Dividend Player | 2023-05-22 | Sporadic | 0 | 0.00% | |
0071.HK | Ex Dividend Knight | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
3311.HK | Ex Dividend Knight | 2023-06-19 | Semi-Annually | 0 | 0.00% | |
1522.HK | Ex Dividend Junior | 2023-06-29 | Sporadic | 0 | 0.00% | |
0564.HK | Ex Dividend Knight | 2023-06-07 | Annually | 0 | 0.00% | |
8490.HK | Ex Dividend Junior | 2023-06-23 | Annually | 0 | 0.00% | |
2039.HK | Ex Dividend Junior | 2023-07-25 | Annually | 0 | 0.00% | |
1100.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.189 | 1.500 | 6.23 | 9.34 | [0 - 0.5] |
returnOnAssetsTTM | 0.150 | 1.200 | 5.01 | 6.01 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.62 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.533 | -1.000 | 4.67 | -4.67 | [0 - 1] |
currentRatioTTM | 2.63 | 0.800 | 1.867 | 1.494 | [1 - 3] |
quickRatioTTM | 2.27 | 0.800 | 1.336 | 1.069 | [0.8 - 2.5] |
cashRatioTTM | 1.180 | 1.500 | 4.56 | 6.83 | [0.2 - 2] |
debtRatioTTM | 0.0151 | -1.500 | 9.75 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 362.23 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.701 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.369 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0210 | -1.500 | 9.92 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.707 | 1.000 | 1.551 | 1.551 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.232 | 1.000 | 7.36 | 7.36 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 10.82 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.794 | 0.800 | 8.04 | 6.43 | [0.5 - 2] |
Total Score | 11.38 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.49 | 1.000 | 9.04 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.11 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.369 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.70 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.701 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.533 | 1.500 | 4.67 | -4.67 | [0 - 1] |
pegRatioTTM | -0.257 | 1.500 | -5.04 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.205 | 1.000 | 7.37 | 0 | [0.1 - 0.5] |
Total Score | 5.59 |
CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej